BeiGene, Ltd. (NASDAQ:BGNE - Get Rating) Chief Financial Officer Julia Aijun Wang sold 295 BeiGene shares in a trade dated Friday, July 1. The shares were sold at an average price of $158.50, for a total value of $46,757.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, accessible via the SEC’s website.
Julia Aijun Wang also recently made the following trade(s):
- On Friday, June 17, Julia Aijun Wang sold 161 BeiGene shares. The stock was sold at an average price of $136.64, for a total value of $21,999.04.
The NASDAQ BGNE traded $27.53 during Tuesday’s trading, hitting $194.48. The stock recorded a trading volume of 475,676 shares, compared to an average volume of 315,405 shares. The company has a market capitalization of $20.09 billion, a PE ratio of -9.68 and a beta of 0.72. The company’s 50-day moving average price is $145.77 and its two-hundred-day moving average price is $190.10. The company has a debt ratio of 0.03, a quick ratio of 4.87 and a current ratio of 5.05. BeiGene, Ltd. has a 12-month low of $118.18 and a 12-month high of $426.56.
BeiGene (NASDAQ:BGNE - Get Rating) last reported quarterly earnings data on Thursday, May 5. The company reported ($4.24) earnings per share (EPS) for the quarter, beating analyst consensus estimates of ($4.52) by $0.28. BeiGene had a negative return on equity of 40.10% and a negative net margin of 218.25%. The company posted revenue of $306.60 million for the quarter, compared to $300.41 million expected by analysts. The company’s quarterly revenue was down 49.4% year over year. As a group, stock analysts predict that BeiGene, Ltd. will show earnings per share of -15.54 for the current fiscal year.
BGNE has been the subject of several research reports. Morgan Stanley raised its price target on BeiGene from $330.00 to $338.00 and gave the stock an “overweight” rating in a Tuesday, April 12 research report. StockNews.com downgraded BeiGene from a “hold” rating to a “sell” rating in a Thursday, June 16 research report. Finally, SVB Leerink downgraded BeiGene from an “outperforming” rating to a “market performing” rating and lowered its target price for the stock from $300.00 to $177.00 in a research report from the Thursday March 17. One research analyst rated the stock with a sell rating, one issued a hold rating and five issued a buy rating for the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $315.33.
Several institutional investors have recently changed their positions in BGNE. Capital International Investors increased its stake in BeiGene shares by 11.2% during the 1st quarter. Capital International Investors now owns 7,055,295 shares of the company worth $1,337,378,000 after purchasing an additional 711,396 shares last quarter. Bank of America Corp DE increased its stake in BeiGene shares by 77.1% during the 1st quarter. Bank of America Corp DE now owns 414,466 shares of the company worth $78,169,000 after acquiring an additional 180,470 shares in the last quarter. Bridgewater Associates LP increased its equity stake in BeiGene by 67.3% during the 1st quarter. Bridgewater Associates LP now owns 383,818 shares of the company worth $72,388,000 after acquiring an additional 154,335 shares in the last quarter. Zeal Asset Management Ltd increased its stake in BeiGene shares by 266.3% during the 1st quarter. Zeal Asset Management Ltd now owns 194,838 shares in the company worth $38,098,000 after acquiring an additional 141,646 shares in the last quarter. Finally, Capital Group International Inc. CA increased its stake in BeiGene shares by 14.1% during the 1st quarter. Capital Group International Inc. CA now owns 1,140,960 shares of the company worth $215,185,000 after acquiring an additional 141,133 shares in the last quarter.
BeiGene Company Profile (Get an assessment)
BeiGene, Ltd., a biotechnology company, focuses on the discovery, development, manufacture and marketing of various drugs globally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat classic R/R Hodgkin’s lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukaemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric Castleman’s disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer and non-small cell lung cancer (NSCLC).
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in BeiGene right now?
Before you consider BeiGene, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and BeiGene wasn’t on the list.
Although BeiGene currently has a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here